# US 2021/0024940 A1 · Recombinant therapeutic interventions for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0024940 A1
- Document ID: US20210024940A1
- Status: Published application
- Kind: A1
- Application number: 16/638,943
- Filed: 2019-03-14
- Published: 2021-01-28
- Earliest claimed: 2018-04-17
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: William R. Bishai; Trinity J. Bivalacqua; Alok Kumar Singh; Monali Praharaj; Takahiro Yoshida
- Web page: https://patentgrep.com/patent/US20210024940A1

## CPC

- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/88: Lyases (4.)
- C12N 9/93: {Ligases (6)}
- C12Y 207/07: Nucleotidyltransferases (2.7.7)
- C12Y 401/01011: Aspartate 1-decarboxylase (4.1.1.11)
- C12Y 401/01012: Aspartate 4-decarboxylase (4.1.1.12)
- C12Y 603/02001: Pantoate-beta-alanine ligase (6.3.2.1)
- A61K 2039/523: {expressing foreign proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Described are compositions and methods for treating or preventing cancer in a subject by administering a pharmaceutical composition comprising a strain of Mycobacteria including an expression vector of the present invention into the bladder of a subject. The pharmaceutical composition may be administered by any suitable means including by a catheter.

## Claims

### Claim 1

A vector comprising a nucleic acid sequence expressing a protein or functional part thereof that makes a STING agonist.

### Claim 2 (depends on 1)

The vector of claim 1 wherein the STING agonist is selected from the group consisting of 3′-5′ c-di-AMP (also known as c-di-AMP); 3′-5′ c-di-GMP (also known as c-di-GMP); 3′-3′cGAMP ; 2′-3′cGAMP and a combination thereof.

### Claim 3 (depends on 2)

The vector of claim 2 comprising the nucleic acid sequence selected from the group consisting of a first nucleic acid sequence encoding a Rv1354c protein, or a functional part thereof; a second nucleic acid sequence encoding a 3′-3′ cyclic GMP-AMP synthase (DncV) protein, or a functional part thereof; a third nucleic acid sequence encoding a 2′-3′ cyclic GMP-AMP synthase (cGAS) protein, or a functional part thereof; a fourth nucleic acid sequence encoding a DNA integrity scanning (disA) protein, or a functional part thereof and a combination thereof.

### Claim 4 (depends on 1)

The vector of claim 1 further comprising a fifth nucleic acid sequence encoding a PanC and a PanD protein or functional part thereof.

### Claim 5 (depends on 4)

The vector of claim 4 wherein the vector is free of an antibiotic resistance gene.

### Claim 6 (depends on 1)

The vector of claim 1 wherein the vector is selected from the group consisting of a vector that stably integrates into the genome of a bacterium, a vector that stably replicates episomally in multiple copies within a bacterium, and/or a combination thereof.

### Claim 7 (depends on 3)

The vector of claim 3 further comprising a fifth nucleic acid sequence that encodes a protein or nucleic acid sequence that knocks out the expression of a phosphodiesterase gene or a phosphodiesterase domain of a Mycobacterium.

### Claim 8 (depends on 3)

The vector of claim 3 wherein the third nucleic acid sequence overexpresses the cyclase domains of the cyclic GMP-AMP synthase (cGAS) protein.

### Claim 9 (depends on 3)

The vector of claim 3 wherein the third nucleic acid sequence expresses a cyclic GMP-AMP synthase (cGAS) protein having a regulatory DNA recognition capability that is non-functional.

### Claim 10

A strain of Mycobacteria comprising a vector comprising a protein or functional part thereof that makes a STING agonist.

### Claim 11 (depends on 10)

The strain of claim 10 wherein the STING agonist is selected from the group consisting of 3′-5′ c-di-AMP (also known as c-di-AMP); 3′-5′ c-di-GMP (also known as c-di-GMP); 3′ -3′cGAMP; 2′ -3′ cGAMP and a combination thereof.

### Claim 12 (depends on 10)

The strain of claim 10 wherein the a nucleic acid sequence selected from the group consisting of a first nucleic acid sequence encoding a Rv1354c protein, or a functional part thereof a second nucleic acid sequence encoding a 3′-3′ cyclic GMP-AMP synthase (DncV) protein, or a functional part thereof a third nucleic acid sequence encoding a 2′-3′ cyclic GMP-AMP synthase (cGAS) protein, or a functional part thereof a fourth nucleic acid sequence encoding a DNA integrity scanning (DisA) protein, or a functional part thereof and a combination thereof.

### Claim 13 (depends on 12)

The strain of claim 12 wherein the strain of Mycobacteria is Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof.

### Claim 14 (depends on 13)

The strain of claim 13 wherein the strain of Mycobacteria is Mycobacterium bacillus Calmette Guerin (BCG).

### Claim 15 (depends on 14)

The strain of claim 14 wherein the strain is a panthothenate (panCD mutant) auxotroph of BCG and the vector comprises a panCD nucleic acid encoding a PanC protein or a functional part thereof and a nucleic acid sequence encoding a PanD protein or functional part thereof.

### Claim 16 (depends on 16)

The strain of claim 16 wherein the strain is free of a genomic antibiotic resistance gene.

### Claim 17 (depends on 16)

The strain of claim 16, wherein the vector is free of an antibiotic resistance gene.

### Claim 18 (depends on 10)

The strain of claim 10, wherein the vector is selected from a group consisting of a vector that is integrated into the Mycobacterium chromosome, stably replicates episomally in multiple copies with the Mycobacterium, and a combination thereof.

### Claim 19 (depends on 10)

The strain of claim 10 wherein the strain is free of an antibiotic resistance gene.

### Claim 20 (depends on 10)

A pharmaceutical composition, comprising any one of the strains of Mycobacteria of claims 10, and (ii) a pharmaceutically acceptable carrier.

### Claim 21 (depends on 10)

A method of of eliciting a Type 1 interferon response, enhancing the expression of pro-inflammatory cytokine, and/or eliciting trained immunity in subject comprising the steps of:
administering a pharmaceutical composition comprising anyone of the strains strains of Mycobacteria of claims 10, and eliciting a Type 1 interferon response, enhancing the expression of pro-inflammatory cytokine, and/or eliciting trained immunity in the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition is administered into the bladder of the subject by a catheter.

### Claim 23

A method of using a strain of Mycobacteria comprising a vector expressing a protein that makes a STING agonist to treat or prevent cancer in a subject comprising the steps of:
administering a pharmaceutical composition comprising a strain of Mycobacteria comprising a vector expressing a protein that makes a STING agonist or a functional part thereof to a subject having cancer; and
treating or preventing cancer in the subject.

### Claim 24 (depends on 23)

The method of claim 23 wherein the STING agonist is selected from the group consisting of 3′-5′ c-di-AMP (also known as c-di-AMP); 3′-5′ c-di-GMP (also known as c-diGMP); 3′-3′cGAMP; 2′-3′cGAMP and a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24 comprising a nucleic acid sequence selected from the group consisting of a first nucleic acid sequence encoding a Rv1354c protein, or a functional part thereof; a second nucleic acid sequence encoding a 3′-3′cyclic GMP-AMP synthase (DncV) protein, or a functional part thereof; a third nucleic acid sequence encoding a 2′-3′ cyclic GMP-AMP synthase (cGAS) protein, or a functional part thereof; a fourth nucleic acid sequence encoding a DNA integrity scanning (DisA) protein, or a functional part thereof and a combination thereof.

### Claim 26 (depends on 23)

The method of claim 23 wherein the cancer is selected from the group consisting of epithelial cancers, breast cancer, non-muscle invasive bladder cancer, and a combination thereof.

### Claim 27 (depends on 26)

The method of claim 26 wherein the cancer is non-muscle invasive bladder cancer and is a BCG-unresponsive non-muscle invasive bladder cancer (BCG-unresponsive NMIBC) and the pharmaceutical composition is administered by intravesical instillation.

### Claim 28 (depends on 26)

The method of claim 26 wherein the cancer is non-muscle invasive bladder cancer and is a BCG-naïve non-muscle invasive bladder cancer (BCG-naïve NMIBC) and the pharmaceutical composition is administered by intravesical instillation.

### Claim 29 (depends on 26)

The method of claim 26 wherein the epithelial cancer is selected from the group consisting of colon cancer, uterine cancer, cervical cancer, vaginal cancer, esophageal cancer, nasopharyngeal cancer, endobronchial cancer, and a combination thereof and the pharmaceutical composition is administered by to a luminal surface of the epithelial cancer.

### Claim 30 (depends on 23)

The method of claim 23 wherein the cancer is selected from a solid tumor, liquid tumor.

### Claim 31 (depends on 30)

The method of claim 30 wherein the pharmaceutical composition is administered by intratumoral injection.

### Claim 32 (depends on 30)

The method of claim 30 wherein the pharmaceutical composition is administered by systemic infusion.

### Claim 33 (depends on 23)

The method of claim 23 comprising the step of administering a checkpoint inhibitor.

### Claim 34 (depends on 33)

The method of claim 33 wherein the checkpoint inhibitor is selected from the group consisting of ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), cemiplimab (anti-PD-1), atezolizumab (anti-PD-L1), avelumab (anti-PD-L1), durvalumab (anti-PD-L1) and a combination thereof.

### Claim 35 (depends on 23)

The method of claim 23 wherein the cancer is bladder cancer and a catheter administers the pharmaceutical composition.
